These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 30140390)

  • 21. Case report of three EGFR TKI naïve lung adenocarcinoma containing double EGFR mutations (L858R/T790M or Exon 19 Deletion/T790M); Comparing genetic information and histology.
    Sakashita S; Shiba-Ishii A; Murata Y; Sekimoto R; Minami Y; Sato Y; Noguchi M
    Pathol Res Pract; 2018 Aug; 214(8):1224-1230. PubMed ID: 29887244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure.
    Yamaoka T; Ohba M; Arata S; Ohmori T
    J Vis Exp; 2017 Aug; (126):. PubMed ID: 28829429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
    Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
    Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum α-1 Acid Glycoprotein is a Biomarker for the Prediction of Targeted Therapy Resistance in Advanced EGFR-positive Lung Adenocarcinoma.
    Xu YF; Xu Y; Li X; Yang XM
    Comb Chem High Throughput Screen; 2018; 21(10):755-759. PubMed ID: 30663564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.
    Pirazzoli V; Ayeni D; Meador CB; Sanganahalli BG; Hyder F; de Stanchina E; Goldberg SB; Pao W; Politi K
    Clin Cancer Res; 2016 Jan; 22(2):426-35. PubMed ID: 26341921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genome-wide profiling of long non-coding RNA expression patterns in the EGFR-TKI resistance of lung adenocarcinoma by microarray.
    Wu Y; Yu DD; Hu Y; Yan D; Chen X; Cao HX; Yu SR; Wang Z; Feng JF
    Oncol Rep; 2016 Jun; 35(6):3371-86. PubMed ID: 27108960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.
    Tseng JS; Su KY; Yang TY; Chen KC; Hsu KH; Chen HY; Tsai CR; Yu SL; Chang GC
    Oncotarget; 2016 Jul; 7(30):48059-48069. PubMed ID: 27384480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
    Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
    Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between efficacy of the EGFR tyrosine kinase inhibitor and serum tumor markers in lung adenocarcinoma patients.
    Pan JB; Hou YH; Zhang GJ
    Clin Lab; 2014; 60(9):1439-47. PubMed ID: 25291939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.
    Wu SG; Liu YN; Tsai MF; Chang YL; Yu CJ; Yang PC; Yang JC; Wen YF; Shih JY
    Oncotarget; 2016 Mar; 7(11):12404-13. PubMed ID: 26862733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between EGFR-TKI resistance and efficacy of radiotherapy for brain metastases from EGFR-mutant lung adenocarcinoma.
    Hirata H; Nakamura K; Kunitake N; Shioyama Y; Sasaki T; Ohga S; Nonoshita T; Yoshitake T; Asai K; Inoue K; Nagashima A; Ono M; Honda H
    Anticancer Res; 2013 Apr; 33(4):1649-55. PubMed ID: 23564810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutation Profile of Resected
    Zhao ZR; Lin YB; Ng CSH; Zhang R; Wu X; Ou Q; Chen W; Zhou WJ; Lin YB; Su XD; Shao YW; Long H
    Oncologist; 2019 Oct; 24(10):1368-1374. PubMed ID: 30872465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.
    Kinehara Y; Nagatomo I; Koyama S; Ito D; Nojima S; Kurebayashi R; Nakanishi Y; Suga Y; Nishijima-Futami Y; Osa A; Nakatani T; Kato Y; Nishide M; Hayama Y; Higashiguchi M; Morimura O; Miyake K; Kang S; Minami T; Hirata H; Iwahori K; Takimoto T; Takamatsu H; Takeda Y; Hosen N; Hoshino S; Shintani Y; Okumura M; Kumagai T; Nishino K; Imamura F; Nakatsuka SI; Kijima T; Kida H; Kumanogoh A
    JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correction: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer.
    Xu N; Fang W; Mu L; Tang Y; Gao L; Ren S; Cao D; Zhou L; Zhang A; Liu D; Zhou C; Wong KK; Yu L; Zhang L; Chen L
    Oncotarget; 2018 Oct; 9(81):35284. PubMed ID: 30443296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs.
    Mink SR; Vashistha S; Zhang W; Hodge A; Agus DB; Jain A
    Mol Cancer Res; 2010 Jun; 8(6):809-20. PubMed ID: 20530582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
    Zhang C; Cao H; Cui Y; Jin S; Gao W; Huang C; Guo R
    Thorac Cancer; 2021 Oct; 12(19):2574-2584. PubMed ID: 34510760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
    Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
    Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients.
    Yomo S; Oda K
    Lung Cancer; 2018 May; 119():120-126. PubMed ID: 29656746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correction: EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment.
    Zhang H; Zhan C; Ke J; Xue Z; Zhang A; Xu K; Shen Z; Yu L; Chen L
    Oncotarget; 2018 Oct; 9(81):35285. PubMed ID: 30443297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.